ADCs, Multi-Specifics, Combined Therapies and Immunotherapy
6-7 November 2013
This 1½ day conference with an additional plenary session late afternoon on the previous day examines progress in Cancer Biotherapeutics from three key approaches: multi-specific antibody products, antibody drug conjugates, and immunotherapy. It features the key players including Genentech, Merrimack, Immunogen, Mersana, Synthon and Symphogen. This event covers the benefits of simultaneous targeting with synergistic combinations using bi – and multi-specific products. Since the discovery of PD1 and PDL1 attention is turning to immunotherapy, and this topic is covered by reports on progress with immune modulating antibodies and the delivery of cytokines to the tumor. The track also covers advances with the next generation ADCs regarding enhanced payloads, effective novel linkers, better homogeneity of the product, and site specific conjugation.
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab
Luis Borges, Ph.D., Scientific Director, Hematology & Oncology, Amgen, Inc.
Designing Receptor-Binding Proteins with Highly Potent Biological Function
Andreas Plückthun, Ph.D., Director and Professor, Biochemistry, University of Zurich
Two-in-One Antibody Targeting EGFR and HER3: Platform Update
Germaine Fuh, Ph.D., Senior Scientist, Antibody Engineering, Genentech, Inc.
MM-141, a Bispecific Antibody Co-Targeting IGF-1R and Erbb3, Overcomes Network Adaptation by Blocking Redundant Survival Pathways
Jason Baum, Ph.D., Principal Scientist, Research, Merrimack Pharmaceuticals, Inc.
Bispecific κλ-bodies for Selective Inhibition of CD47 in Cancer Cells
Nicolas Fischer, Ph.D., Head, Research, Novimmune SA
Novel Multi-Targeting Antibody Mixtures: Mode of Action and Advantages over Other Approaches
Michael Kragh, Ph.D., Director, Antibody Pharmacology, Symphogen A/S
Targeting Tumor Microenvironmental Signals with Bispecific Antibodies
Alessandro Angelini, Ph.D., David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
Cancer Immunotherapy Using Immune Modulating Antibodies
Andrea van Elsas, CSO, BioNovion B.V.
Immunocytokines: A Novel Potent Class of Armed Antibody
Laura Gualandi, Ph.D., Philochem A.G.
NKTT320: A Humanized Monoclonal Antibody for Cancer Immunotherapy
Robert Mashal, CEO, NKT Therapeutics, Inc.
Novel Tumor-Targeted, Engineered IL-2 Variant (IL-2v)-Based Immunocytokines for Immunotherapy of Cancer
Ekkehard Moessner, Ph.D., Group Leader, Protein Engineering, pRED, Roche Glycart A.G.
Next-Generation ADCs: Enabling Higher Drug Loading, Alternative Payloads, and Alternative Targeting Moieties
Timothy B. Lowinger, Ph.D., CSO, Mersana Therapeutics, Inc.
A Universal Chemically Driven Approach for Constructing Homogeneous ADCs
David Jackson, Ph.D., Principle Scientist, ADC Discovery, Igenica, Inc.
Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody-Drug Conjugates
Pavel Strop, Ph.D., Associate Research Fellow, Protein Engineering, Rinat-Pfizer
Development of Second Generation Duocarmycin ADCs with a Superior Therapeutic Window
Marco Timmers, Ph.D., CSO, New Molecular Entities, Synthon Biopharmaceuticals
Overview of Trastuzumab
Martine Piccart, Head, Medical Oncology, Jules Bordet Institute, Chair, ESMO (European Society for Medical Oncology)
Antibody-Drug Conjugates: From Bench to Bedside and Back
Robert Lutz, Ph.D., Vice President, Translational Research & Development, ImmunoGen, Inc.
Producing Better Antibody-Drug Conjugates (ADCs) Using ThioBridge™ Conjugation
Antony Godwin, Ph.D., Director, Science & Technology, PolyTherics Ltd.